Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06265727 · ClinicalTrials.gov registry record · Phase 1

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

A Phase 1 study of Solid Tumor, Adult, sponsored by Corbus Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
348
Enrollment target
20
Study locations

NCT06265727 is a Phase 1 study of Solid Tumor, Adult that is actively recruiting participants, run by Corbus Pharmaceuticals. The registered enrollment target is 348 participants, above the 186-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (87% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06265727, a Phase 1 study of Solid Tumor, Adult, is actively recruiting participants, sponsored by Corbus Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
348 participants
Enrollment target
20
Study locations

Study Summary

The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to answer are: What is the the safe and effective dose of CRB-701? What cancers can be treated effectively with CRB-701? Participants will be asked to attend clinic and be given a intravenous infusion of CRB-701. They will have blood tests, CT or MRI Scans, and other assessments to measure whether CRB-701 has an effect on tumors.

Conditions Studied

Solid Tumor, Adult

Interventions

  • DRUG CRB-701
  • DRUG Anti-PD-1

Study Locations (20)

Other

  • ICM-Val d'Aurelle - Montpellier
  • CHU de Poitiers - Poitiers
  • Institut de Cancerologie de l'Ouest - Saint-Herblain
  • Gustave Roussy - Villejuif
  • Careggi University Hospital - Florence

California

  • City of Hope Cancer Center - Duarte
  • Moores Cancer Centre at UC San Diego Health - San Diego
  • Helen Diller Family Comprehensive Cancer Center - UCSF - San Francisco

Illinois

  • University of Chicago - Chicago
  • Hope and Healing Cancer Center - Hinsdale

Alabama

  • O'Neal Comprehensive Cancer Center at University of Alabama-Birmingham - Birmingham

Colorado

  • Rocky Mountain Cancer Centres - Denver

Connecticut

  • Yale Cancer Center - New Haven

Florida

  • Florida Cancer Specialists - Orlando

Massachusetts

  • Dana-Faber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 348 participants
Start Date 2024-04-01
Est. Completion 2027-01-27
Phase Phase 1

Sponsor

Corbus Pharmaceuticals

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06265727

The ClinicalTrials.gov registry entry for NCT06265727 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 348 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 186-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (87% higher). The listed sponsor is Corbus Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumor, Adult appearing as the primary indexed condition, and to 2 interventions - of which CRB-701 is the first listed.

NCT06265727 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT06265727 about?

NCT06265727 is a clinical study titled "A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors". The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to answer are: What is the the safe and effective dose of CRB-701? What cancers can be treated effectively ...

What is the current status of trial NCT06265727?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 348 participants. The study started on 2024-04-01. Estimated completion is 2027-01-27.

What conditions does trial NCT06265727 study?

This clinical trial studies the following conditions: Solid Tumor, Adult.

What interventions are being tested in trial NCT06265727?

The interventions under investigation include: CRB-701 (DRUG), Anti-PD-1 (DRUG).

Who is sponsoring clinical trial NCT06265727?

This trial is sponsored by Corbus Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06265727 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor, Adult

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor, Adult

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.